meglumine antimoniate
Selected indexed studies
- Systemic meglumine antimoniate-induced severe dilated cardiomyopathy. (Dermatol Ther, 2022) [PMID:36193752]
- In vivo efficacy of meglumine antimoniate-loaded nanoparticles for cutaneous leishmaniasis: a systematic review. (Nanomedicine (Lond), 2021) [PMID:34189952]
- Comparison of Meglumine Antimoniate and Miltefosine in Cutaneous Leishmaniasis. (J Coll Physicians Surg Pak, 2023) [PMID:38062590]
_Worker-drafted node — pending editorial review._
Connections
meglumine antimoniate is a side effect of
Sources
- Systemic meglumine antimoniate-induced severe dilated cardiomyopathy. (2022) pubmed
- In vivo efficacy of meglumine antimoniate-loaded nanoparticles for cutaneous leishmaniasis: a systematic review. (2021) pubmed
- Comparison of Meglumine Antimoniate and Miltefosine in Cutaneous Leishmaniasis. (2023) pubmed
- [Meglumine antimoniate]. (2001) pubmed
- Meglumine Antimoniate-Loaded Aqueous-Core PLA Nanocapsules: Old Drug, New Formulation against Leishmania-Related Diseases. (2021) pubmed
- Hypersensitivity eosinophilic myocarditis possibly triggered by meglumine antimoniate. (2024) pubmed
- Comparison of meglumine antimoniate versus miltefosine in the treatment of new world cutaneous leishmaniasis: a systematic review and meta-analysis. (2026) pubmed
- Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis. (2019) pubmed
- AgNP-PVP-meglumine antimoniate nanocomposite reduces Leishmania amazonensis infection in macrophages. (2021) pubmed
- Meglumine antimoniate was associated with a higher cure rate than liposomal amphotericin B in the treatment of American tegumentary leishmaniasis: A retrospective cohort study from a Leishmania braziliensis-endemic area. (2022) pubmed